U nas zapłacisz kartą
Brymonidyna na twarz - Tajemnicze Piękno Naturalnej Pielęgnacji
How should I use brimonidine ophthalmic?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Wash your hands before using the eye drops.
Use only the number of drops your doctor has prescribed.
Do not touch the tip of the eye dropper or place it directly on your eye. A contaminated dropper can infect your eye, which could lead to serious vision problems.
Wait at least 5 minutes before using any other eye drops your doctor has prescribed.
Do not use the eye drops if the liquid looks cloudy, has changed colors, or has particles in it. Call your pharmacist for new medicine.
Store at room temperature away from moisture and heat. Do not freeze. Keep the bottle tightly closed when not in use.
Pharmacology
Brinzolamide, either as a standalone agent or in combination with brimonidine, is approved by the FDA for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. 8,5 Brinzolamide is also approved in Europe to be used in combination with timolol to treat the same conditions. 7
Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. Build, train, & validate predictive machine-learning models with structured datasets.Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Avoid life-threatening adverse drug events with our Clinical APIInhibition of carbonic anhydrase II (CA-II) in the ciliary process of the eye slows the formation of bicarbonate and thus fluid flow, lowering intraocular pressure (IOP). 3,4
The IOP-reducing effect of brinzolamide as adjunctive therapy to the prostaglandin analog travoprost was studied. Following a 4-week run-in with travoprost, patients with an IOP ≥19 mmHg were randomized to receive added treatment with brinzolamide or timolol. An additional decrease in mean diurnal IOP of 3.2 to 3.4 mmHg for the brinzolamide group and 3.2 to 4.2 mmHg for the timolol group were observed. There was an overall higher incidence of non-serious ocular adverse reactions, mainly related to signs of local irritation, in the brinzolamide/travoprost groups. The events were mild and did not affect the overall discontinuation rates in the studies. 11
A clinical trial was conducted with brinzolamide in 32 pediatric patients less than 6 years of age, diagnosed with glaucoma or ocular hypertension. Some patients were naive to IOP therapy whilst others were on other IOP-lowering medicinal product(s). Those who had been on previous IOP medicinal products were not required to discontinue their IOP medicinal product(s) until the initiation of monotherapy with brinzolamide. 11
References
1. Cantor L.B. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert. Opin. Pharmacother. 2000, 1 :815–834. doi: 10.1517/14656566.1.4.815. [PubMed] [CrossRef] [Google Scholar]
2. Lusthaus J.A., Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension, a safety evaluation. Expert. Opin. Drug Saf. 2017, 16 :1071–1078. doi: 10.1080/14740338.2017.1346083. [PubMed] [CrossRef] [Google Scholar]
3. Kingman S. Glaucoma is second leading cause of blindness globally. Bull. World Health Organ. 2004, 82 :887. [PMC free article] [PubMed] [Google Scholar]
4. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014, 121 :2081. doi: 10.1016/j.ophtha.2014.05.013. [PubMed] [CrossRef] [Google Scholar]
5. Kapetanakis V.V., Chan M.P.Y., Foster P.J., Cook D.G., Owen C.G., Rudnicka A.R. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): A systematic review and meta-analysis. Br. J. Ophthalmol. 2016, 100 :86. doi: 10.1136/bjophthalmol-2015-307223. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Mukesh B.N., McCarty C.A., Rait J.L., Taylor H.R. Five-year incidence of open-angle glaucoma: The visual impairment project. Ophthalmology. 2002, 109 :1047. doi: 10.1016/S0161-6420(02)01040-0. [PubMed] [CrossRef] [Google Scholar]
7. Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007, 114 :1965. doi: 10.1016/j.ophtha.2007.03.016. [PubMed] [CrossRef] [Google Scholar]
8. Chauhan B.C., Mikelberg F.S., Balaszi A.G., LeBlanc R.P., Lesk M.R., Trope G.E., Canadian Glaucoma Study Group Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch. Ophthalmol. 2008, 126 :1030. doi: 10.1001/archopht.126.8.1030. [PubMed] [CrossRef] [Google Scholar]